The VC Endeavour Vision (Switzerland) has finally closed its Endeavour Medtech Growth (EMG) at €250M. This makes it one of the largest funds dedicated to MedTech innovation worldwide!
Largely oversubscribed, the fund reached its hard cap and closed well above its €150M target, finally reaching €250M – the largest fund dedicated to medtech in Europe, and one of the largest pure medtech funds ever…
EMG is targeting high potential European and US companies in the medical device and digital health sectors. To qualify, these have to demonstrate ‘innovative solutions’ for the health sector, which have also already gained regulatory approval and are starting to generate commercial traction.
Examples include Sophia Genetics (Switzerland), which is a genomics specialist (and the first bioinformatics company in Europe allowed to analyse clicnical data with NGS), also nominated in the top 10 of 100 Swiss start-up awards last year.
But larger biotechs have also been supported by EMG, such as Actelion (also Swiss) –